Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients
with chronic venous disease of the lower extremities.
The primary hypothesis is that more patients will achieve a decrease in rVCSS score of at
least 4 points with sulodexide than with placebo.